ArticleHuman gene therapy2012
A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.
Article in Human gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Specific Cell Targeting byCells · 2024Article
- A Brief Introduction to Current Cancer Gene Therapy.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Metabolome-Driven Regulation of Adenovirus-Induced Cell Death.International journal of molecular sciences · 2021Review
- Prostate Microbiota and Prostate Cancer: A New Trend in Treatment.Frontiers in oncology · 2021Review
- Hitting the Target but Missing the Point: Recent Progress towards Adenovirus-Based Precision Virotherapies.Cancers · 2020Review
- Adenoviral vectors for in vivo delivery of CRISPR-Cas gene editors.Journal of controlled release : official journal of the Controlled Release Society · 2020Review
- Designer Oncolytic Adenovirus: Coming of Age.Cancers · 2018Review
- Development of an adenovirus vector vaccine platform for targeting dendritic cells.Cancer gene therapy · 2018Article
- Targeting strategies of adenovirus‑mediated gene therapy and virotherapy for prostate cancer (Review).Molecular medicine reports · 2017Review
- Article
- Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Human gene therapy · 2014Review
- High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus.Cancer gene therapy · 2014Article
- Peptide-based technologies to alter adenoviral vector tropism: ways and means for systemic treatment of cancer.Viruses · 2014Review
- New viruses for cancer therapy: meeting clinical needs.Nature reviews. Microbiology · 2014Review
- Development of a generic adenovirus delivery system based on structure-guided design of bispecific trimeric DARPin adapters.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Article
- Chapter two--Adenovirus strategies for tissue-specific targeting.Advances in cancer research · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
Abstract
The efficacy of adenovirus (Ad)-based gene therapy of solid tumors, such as prostate cancer, is limited. One of the many problems is that the virus infects many different cell types in the body, resulting in high toxicity, whereas the target cancer cells are often less prone to wild-type Ad infection. Our aim was to develop genetically de- and retargeted Ad vectors to reduce off-target effects and increase target infection for prostate cancer. We have previously reported an Ad5 vector specific for the cancer-associated receptor Her2/neu, created by inserting Her2/neu-reactive Affibody(®) molecules (ZH) into the HI loop of a coxsackievirus and adenovirus receptor binding-ablated fiber (Ad[ZH/1]). In addition to virus retargeting to Her2/neu, this virus was further modified from wild-type Ad by changing the RGD motif in the penton base to EGD and by substitution of the KKTK motif in the third shaft repeat to RKSK, resulting in the vector Ad[ZH/3]. The ZH-containing vectors could be produced to high titers and were specific for their target, resulting in efficient infection and killing of Her2/neu-positive androgen-dependent PC346C prostate cancer cells in vitro. Here we show that the oncolytic Ad[ZH/3] vector significantly prolonged survival time and reduced serum prostate-specific antigen levels in an orthotopic prostate tumor model in nude mice to the same extent as wild-type Ad5. Our results show that Her2/neu targeting using Ad-based vectors for prostate cancer is feasible and may serve as a basis for the development of gene therapy of human prostate cancer as well as other Her2/neu-expressing cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.